hit counter

Ubiquinol for Multiple System Atrophy: First Positive Repurposing Trial

Photoreal illustration of misfolded alpha-synuclein in glial cells with drug molecule motifs, representing repurposed-drug therapeutics in MSA.

Multiple system atrophy is a rapidly progressive neurodegenerative disease with no proven disease-modifying therapy. A 2026 review by Jeong and colleagues tracks two decades of repurposed-drug trials, with one recent positive Phase 2 result.1 Research Highlights Multiple system atrophy (MSA) is a fatal α-synuclein disorder distinct from Parkinson’s disease. It progresses faster than PD (median …

Read more